HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,054,852 | -37.4% | 237,038 | -40.9% | 0.01% | -33.3% |
| Q2 2023 | $14,466,126 | +67.2% | 401,057 | +77.1% | 0.02% | +63.6% |
| Q1 2023 | $8,649,729 | -43.1% | 226,492 | -15.2% | 0.01% | -47.6% |
| Q4 2022 | $15,203,679 | +34.7% | 267,200 | -6.4% | 0.02% | +31.2% |
| Q3 2022 | $11,286,455 | +134.2% | 285,444 | +160.6% | 0.02% | +33.3% |
| Q2 2022 | $4,820,000 | -52.2% | 109,552 | -56.6% | 0.01% | -42.9% |
| Q1 2022 | $10,074,000 | -3.6% | 252,630 | -2.8% | 0.02% | +5.0% |
| Q4 2021 | $10,449,000 | -42.7% | 259,852 | -42.1% | 0.02% | -45.9% |
| Q3 2021 | $18,245,000 | +71.3% | 448,510 | +91.2% | 0.04% | +76.2% |
| Q2 2021 | $10,650,000 | +17.2% | 234,535 | +7.6% | 0.02% | +16.7% |
| Q1 2021 | $9,090,000 | -11.8% | 218,032 | -9.6% | 0.02% | -14.3% |
| Q4 2020 | $10,304,000 | +737.0% | 241,257 | +415.0% | 0.02% | +600.0% |
| Q3 2020 | $1,231,000 | -2.0% | 46,842 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,256,000 | +1.8% | 46,842 | -31.7% | 0.00% | 0.0% |
| Q1 2020 | $1,234,000 | -1.0% | 68,567 | -2.5% | 0.00% | 0.0% |
| Q4 2019 | $1,247,000 | +51.5% | 70,314 | +32.5% | 0.00% | +50.0% |
| Q3 2019 | $823,000 | -9.7% | 53,049 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $911,000 | +9.8% | 53,049 | +2.8% | 0.00% | 0.0% |
| Q1 2019 | $830,000 | +9.9% | 51,582 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $755,000 | -16.6% | 51,582 | +3.5% | 0.00% | 0.0% |
| Q3 2018 | $905,000 | +7.6% | 49,834 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $841,000 | -19.1% | 49,834 | -6.0% | 0.00% | 0.0% |
| Q1 2018 | $1,039,000 | -3.3% | 53,034 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $1,074,000 | +16.6% | 53,034 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $921,000 | +41.7% | 53,034 | +4.5% | 0.00% | +100.0% |
| Q2 2017 | $650,000 | -96.8% | 50,728 | -96.7% | 0.00% | -97.8% |
| Q1 2017 | $20,105,000 | +27.0% | 1,551,283 | -3.2% | 0.05% | +21.1% |
| Q4 2016 | $15,830,000 | -23.2% | 1,602,192 | -6.1% | 0.04% | -2.6% |
| Q3 2016 | $20,606,000 | +27.3% | 1,705,777 | -9.1% | 0.04% | -2.5% |
| Q2 2016 | $16,189,000 | +17.1% | 1,875,872 | +28.5% | 0.04% | +17.6% |
| Q1 2016 | $13,820,000 | -5.3% | 1,459,396 | +73.2% | 0.03% | -5.6% |
| Q4 2015 | $14,599,000 | +14.2% | 842,421 | -11.5% | 0.04% | +12.5% |
| Q3 2015 | $12,783,000 | -41.0% | 951,846 | -0.8% | 0.03% | -36.0% |
| Q2 2015 | $21,660,000 | +9.6% | 959,251 | -30.7% | 0.05% | +13.6% |
| Q1 2015 | $19,766,000 | +27.7% | 1,384,182 | -13.7% | 0.04% | +29.4% |
| Q4 2014 | $15,481,000 | +22.1% | 1,604,282 | +15.2% | 0.03% | +17.2% |
| Q3 2014 | $12,677,000 | +26.1% | 1,393,082 | +36.9% | 0.03% | +26.1% |
| Q2 2014 | $10,054,000 | +33.9% | 1,017,582 | +72.1% | 0.02% | +35.3% |
| Q1 2014 | $7,509,000 | +724.3% | 591,182 | +872.6% | 0.02% | +750.0% |
| Q4 2013 | $911,000 | +35.8% | 60,782 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $671,000 | +38.9% | 60,782 | 0.0% | 0.00% | +100.0% |
| Q2 2013 | $483,000 | – | 60,782 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |